Mesa Laboratories (MLAB) 44th Annual J.P. Morgan Healthcare Conference summary

Business Overview and Strategy

• Focuses on mission-critical quality controls for regulated markets, supporting drug development, bioproduction, and healthcare delivery, with an emphasis on protecting vulnerable populations.

• Operates in diversified, high-growth verticals: sterility controls, biopharmaceutical development, genomics, and calibration solutions, with little exposure to NIH funding.

• Maintains a disciplined management team with deep industry experience and a proprietary lean-based operating model called the Mesa Way.

• Expands through accretive, strategic M&A, leveraging complementary products and geographic reach, especially in APAC.

• 75%+ of revenue is recurring, driven by consumables and services embedded in regulated workflows, reducing volatility.

Financial Performance and Growth

• FY25 revenues reached $241M, with a five-year CAGR of 15.4% and core organic revenue growth of 5%.

• Gross profit margin for FY25 was 62.6%, with strong operating leverage and AOI excluding unusual items at 23.5% of revenue.

• Long-term financial performance shows a 2015-25 CAGR of 13% for revenues and 9% for AOI.

• Recent acquisitions, such as GKE, have been accretive to revenue and financial metrics, with projected GKE revenues of $21M–$22M and AOI margins of 37–40%.

• Balance sheet improvements include $21.3M in cash and a net leverage ratio reduced from 3.8x to 3.02, with plans to deleverage further.

Market Dynamics and Outlook

• Headwinds included bioprocess destocking, academic funding shifts, CapEx cycles, regulatory changes, and China-related challenges, most of which are now easing.

• Clinical trial starts are a key leading indicator; as these recover, growth is expected to accelerate.

• Expects mid-single-digit or higher organic growth as market conditions normalize, with potential for high single-digit or double-digit growth through acquisitions.

• Lean-based operating model enables rapid adaptation to market changes, supporting profitability even during volatility.

• Strategic focus remains on sustainable, high-quality growth and improving the balance sheet.